研究单位：[1]Xuan Wu Hospital, Capital Medical University,Beijing,Beijing,China,100053[2]The Michael J. Fox Foundation for Parkinson's Research[3]XINGIMAGING LLC[4]Naming MITRO Pharmaceutical Technology Co., Ltd
A total of 38 patients with early-stage Parkinson's disease and 38 patients with prodromal Parkinson's disease are planned to be enrolled in this study and examined for longitudinal changes in [18F]AV-133 through follow-up, thereby informing the design of future therapeutic trials utilizing [18F]AV-133 as a marker of disease progression.
